Video claim watch

Injectable Peptides for Anti-Aging? A Dermatologist Explains GHK-Cu

A board-certified dermatologist separates topical copper-peptide evidence from the newer injectable GHK-Cu trend using a clear, product-specific visual explainer.

Dr Dray channel11:44 runtime82K views when checked

Published Apr 22, 2026. Metadata checked Jul 10, 2026.

Watch on YouTube

Transcript review

7 material claims logged

Published with source gaps audit stateauto-captioned transcript0 operational-guidance flags2 source gaps

Reviewed Jul 12, 2026. Next review Aug 12, 2026.

strong evidence-literacy signal with a few mechanistic statements that still need sourcing.

YouTube auto-caption available; 10 creator chapters.

Claim-by-claim audit

What the video says, and what needs checking

Mechanism

GHK is a naturally occurring glycine-histidine-lysine peptide in plasma and is described as higher in younger people.

Review topic: GHK-Cu / endogenous biology.

Checked against: Primary-source record still needed

primary biochemical literature should be added; not enough to infer benefit from age association.

High-risk mechanism claim

Cell and animal studies are said to support growth-factor signaling, angiogenesis, fibroblast activity, collagen/elastin production, and wound repair.

Review topic: GHK-Cu / skin / wound healing.

Checked against: Topical GHK-Cu gel for acute skin wound healing, Topical copper tripeptide complex after laser skin resurfacing

clearly separate preclinical mechanisms from clinical outcomes.

High-risk evidence claim

Human trials are characterized as small and insufficient for meaningful efficacy conclusions.

Review topic: GHK-Cu evidence grade.

Checked against: Topical GHK-Cu gel for acute skin wound healing, Topical copper tripeptide complex after laser skin resurfacing

High-risk evidence claim

“Boost collagen/reverse aging” claims are biologically plausible but not established as clinical anti-aging effects.

Review topic: GHK-Cu / cosmetic claims.

Checked against: Topical copper tripeptide complex after laser skin resurfacing

High-risk evidence claim

Hair-growth arguments rely mainly on mechanisms and lab models; GHK-Cu is not standard-of-care hair-loss treatment.

Review topic: GHK-Cu / hair.

Checked against: Primary-source record still needed

primary hair studies required; do not infer from related copper peptides.

High-risk evidence claim

Brain-health and longevity claims are described as animal-only and unconfirmed in humans.

Review topic: GHK-Cu / cognition / longevity.

Checked against: FDA BPC-157 compounding safety risk: immunogenicity

registry search plus R-GHK-1.

High-risk regulatory claimHigh-risk safety claimHigh-risk quality claim

Injectable GHK-Cu is described as unapproved, without standardized dosing or meaningful human safety data, and vulnerable to purity/contamination problems.

Review topic: GHK-Cu / compounding.

Checked against: FDA BPC-157 compounding safety risk: immunogenicity, Compounding and the FDA: Questions and Answers

Connected research

Compounds discussed

GHK-Cu GHK-Cu is a copper-binding tripeptide studied mainly in topical skin contexts. In the reviewed sources, one small randomized human study found no objective advantage after laser resurfacing, a Phase 2 topical-wound trial is still recruiting, and comparable human evidence for injectable or systemic claims was not identified.

Source check

Records used in this claim audit

Topical GHK-Cu gel for acute skin wound healing

ClinicalTrials.gov · Primary regulatory · Feb 27, 2026 · accessed Jul 16, 2026

Recruiting Phase 2 registry record for a randomized, blinded, vehicle-controlled split-wound study of topical GHK-Cu gel in an estimated 60 healthy adults. No results are posted.

2 linked pagesOpen original · clinicaltrials-ghkcu-wound-2026

Topical copper tripeptide complex after laser skin resurfacing

National Library of Medicine · Peer reviewed · 2006 · accessed Jul 16, 2026

Randomized topical study with 13 completers after CO2 laser resurfacing. Objective erythema, wrinkle, and overall skin-quality outcomes did not differ between groups, while patient satisfaction was higher with the GHK-Cu regimen.

5 linked pagesOpen original · pubmed-ghkcu-postlaser-2006

Certain bulk drug substances for use in compounding may present significant safety risks

U.S. Food and Drug Administration · Primary regulatory · Apr 22, 2026 · accessed Jul 16, 2026

FDA risk page lists BPC-157: compounded BPC-157 may pose immunogenicity risk and peptide-related impurity concerns for certain routes of administration.

41 linked pagesOpen original · fda-bulk-risk-list

Compounding and the FDA: Questions and Answers

U.S. Food and Drug Administration · Primary regulatory · accessed Jul 12, 2026

FDA reference explaining the statutory distinction between compounded drugs and FDA-approved drugs.

7 linked pagesOpen original · fda-compounding-questions-answers